News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1โ€“36
Matches
118
Sources here
15
Companies here
1
Search results Stored financial headlines

Active search

118 matching headlines

Ticker or company: TN8Main companies and provider mentions
Clear

Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026

New development solutions, expanded global capacity, and advanced digital technologies help pharma and biotech companies reduce complexity and scale toward commercialization Key facts New solutions for drug product development: New OSD Express and Steriles Express Solutions provide defined development approaches designed to increase predictability โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Thermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study

Initial results presented at HUPO 2026 World Congress demonstrate how the company's complementary mass spectrometry and Olink biomarker panels can expand biological associations at population scale to advance disease and therapeutic development research Key Takeaways: Thermo Fisher's complementary proteomic technologies uncovered more than 2,500 โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Thermo Fisher Scientific (TMO) Stock Seems Reasonable Following Its 47% Run

Thermo Fisher Scientific has been a strong performer over the past year, and that kind of run naturally raises a pointed question for anyone looking at the stock today. Is the current share price aligned with the cash flows the business is expected to โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Thermo Fisher (TMO) Is Turning Innovation Into Recurring Revenue. Can Margins Follow?

On September 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Will Thermo Fisherโ€™s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative

Earlier this month, Thermo Fisher Scientific announced several product and collaboration updates, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep's Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?

Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead's momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026

WALTHAM, Mass., September 28, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2026 before the market opens on Wednesday, October 21, 2026, and will hold a conference โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno

Evosep Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflows SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosepโ„ข, a global leader in standardized proteomics solutions, today announced a reseller agreement with Thermo Fisher Scientific, โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?

Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. Another factor that can influence investors is FOMO, or the fear of โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Thermo Fisher Scientific (TMO) Launches Gibco CHO K1 Panel On A Fair Value Question

Thermo Fisher Scientific (TMO) has introduced the Gibco CHO-K1 Catalog Panel, a cGMP-ready media portfolio aimed at improving cell growth, protein yield, and workflow flexibility for biologics and biosimilars developers. Thermo Fisher Scientific sits at US$665.30 per share after a 30-day share price return โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Thermo Fisher Scientific (TMO) Rolls Out New Media Panel For Biologics Development

Thermo Fisher Scientific (NYSE:TMO) has introduced the Gibco CHO-K1 Catalog Panel, a new off the shelf media offering for biologics developers. The panel includes cGMP ready, chemically defined, animal origin free basal and feed media aimed at broad process development and manufacturing use. The โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Thermo Fisher Scientific Launches Gibcoโ„ข CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development

New cGMP-ready media and feed panel helps developers rapidly identify high-performing combinations, with study results demonstrating up to 73% higher titer versus benchmark catalog media and feeds and up to 202% higher peak viable cell density compared with benchmark products tested Key facts Product: โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue

Company Logo High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Content Screening (HCS) - Global Strategic Business Report" has โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Capitalize on the High Throughput Screening Shift: Track Thermo Fisher, Agilent, Danaher, Revvity and Tecan as AI-Driven Drug Discovery Reshapes R&D ROI

Company Logo AI, automation, robotics, microfluidics and nanotechnology are advancing HTS, while personalized medicine, biologics, research funding and pharma-academia partnerships drive demand. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Throughput Screening (HTS) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Thermo Fisher Scientific (TMO) is Positioned for Resurgence

Fenimore Asset Management, an investment management company, released its Q2 2026 investor letter. You can download the letter here. U.S. equity markets saw broad gains in Q2, driven by strong corporate earnings, economic resilience, and enthusiasm for artificial intelligence (AI). Major indices reached all-time โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Three Analysts, Three Verdicts on Thermo Fisher: Hereโ€™s Who the Numbers Favor

Three Analysts, Three Verdicts on Thermo Fisher: Here's Who the Numbers Favor ยฉTIKR Key Stats for Thermo Fisher Stock Current Price: $641.39 Target Price (Mid): ~$839 Street Target: ~$645 Potential Total Return: ~31% Annualized IRR: ~7% / year What Happened? Thermo Fisher Scientific (TMO) โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Why Is Thermo Fisher Scientific (TMO) Building A Massive Early Disease Data Platform?

Thermo Fisher Scientific (NYSE:TMO) and Mayo Clinic announced the formation of Precure, LLC for early disease detection using multi omic data. Precure plans to integrate proteomic, genomic, and longitudinal clinical records into a single biomedical dataset to identify early disease signals. The collaboration positions โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Thermo Fisher Sees Stronger Demand, Calls 2026 an โ€˜Outstanding Yearโ€™

Key Points Interested in Thermo Fisher Scientific Inc.? Here are five stocks we like better. Thermo Fisher raised its outlook after returning to 5% organic growth in the second quarter, with adjusted EPS up 13%. CEO Marc Casper expects about 4% organic growth in โ€ฆ

TN8 main company
Sharemaestro market context Trend signal active 52 weeks +28.1% TN8 stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context